{"id":72366,"date":"2026-08-12T12:23:59","date_gmt":"2026-08-12T04:23:59","guid":{"rendered":"https:\/\/flcube.com\/?p=72366"},"modified":"2026-08-12T12:24:00","modified_gmt":"2026-08-12T04:24:00","slug":"insilico-medicine-nominates-ism0900-ai-designed-oral-lpa-inhibitor-as-9th-preclinical-candidate-of-2026","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=72366","title":{"rendered":"Insilico Medicine Nominates ISM0900, AI\u2011Designed Oral Lp(a) Inhibitor, as 9th Preclinical Candidate of 2026"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Insilico Medicine<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/beta\/quote\/3696:HKG\">HKG: 3696<\/a>) announced the nomination of <strong>ISM0900<\/strong> \u2014 a <strong>potent, highly selective, oral small\u2011molecule inhibitor powered by AI<\/strong> \u2014 as a <strong>Preclinical Candidate (PCC)<\/strong>. Targeting <strong>lipoprotein(a), or Lp(a)<\/strong>, for <strong>cardiovascular risk management<\/strong>, ISM0900 marks the <strong>9th PCC nominated by Insilico Medicine since the start of 2026<\/strong>.<\/p>\n\n\n\n<h2 id=\"h-nomination-overview\" class=\"wp-block-heading\">Nomination Overview<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Company<\/strong><\/td><td>Insilico Medicine (HKG: 3696)<\/td><\/tr><tr><td><strong>Candidate<\/strong><\/td><td>ISM0900<\/td><\/tr><tr><td><strong>Modality<\/strong><\/td><td>Potent, highly selective, oral small\u2011molecule inhibitor<\/td><\/tr><tr><td><strong>Target<\/strong><\/td><td>Lipoprotein(a) \/ Lp(a)<\/td><\/tr><tr><td><strong>Therapeutic Area<\/strong><\/td><td>Cardiovascular risk management<\/td><\/tr><tr><td><strong>Discovery Platform<\/strong><\/td><td>Insilico Medicine&#8217;s proprietary generative AI platform<\/td><\/tr><tr><td><strong>Milestone<\/strong><\/td><td>Preclinical Candidate (PCC) nomination \u2014 9th since the start of 2026<\/td><\/tr><tr><td><strong>Announcement Date<\/strong><\/td><td>12 Aug 2026<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-drug-profile-amp-mechanism\" class=\"wp-block-heading\">Drug Profile &amp; Mechanism<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>AI\u2011Powered Discovery:<\/strong> Empowered by Insilico Medicine&#8217;s <strong>proprietary generative AI platform<\/strong>, ISM0900 features a <strong>novel molecular structure<\/strong>.<\/li>\n\n\n\n<li><strong>Dual Mechanism:<\/strong> The candidate <strong>selectively blocks the Lp(a) signaling cascade<\/strong> and <strong>inhibits its synthesis at the source<\/strong>, an approach designed to address Lp(a) at both production and activity levels.<\/li>\n\n\n\n<li><strong>Oral Delivery:<\/strong> As an <strong>oral small molecule<\/strong>, ISM0900 offers a potential convenience advantage over injectable Lp(a)\u2011lowering modalities in development.<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-disease-context\" class=\"wp-block-heading\">Disease Context<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Independent Risk Factor:<\/strong> Research shows that <strong>Lp(a) is an independent risk factor for atherosclerotic cardiovascular disease (ASCVD) and major adverse cardiovascular events<\/strong>.<\/li>\n\n\n\n<li><strong>Massive Patient Base:<\/strong> Approximately <strong>20% of the global population<\/strong> is affected by <strong>elevated Lp(a) levels<\/strong> \u2014 a largely untreated risk factor with no approved targeted oral therapy to date.<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-market-impact-amp-outlook\" class=\"wp-block-heading\">Market Impact &amp; Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Hot Target, Crowded Race:<\/strong> Lp(a) has become one of the most closely watched cardiovascular targets in pharma, with multiple RNA\u2011based and antibody approaches in late\u2011stage trials \u2014 yet no approved product, leaving room for a differentiated oral entrant.<\/li>\n\n\n\n<li><strong>AI Pipeline Velocity:<\/strong> The nomination of <strong>9 PCCs within roughly seven months of 2026<\/strong> underscores the pace Insilico Medicine attributes to its generative AI drug\u2011discovery platform, a key differentiator for its business model.<\/li>\n\n\n\n<li><strong>Cardiovascular Franchise Build\u2011Out:<\/strong> The move extends Insilico&#8217;s pipeline beyond its initial oncology and fibrosis focus into cardiometabolic disease, one of the largest therapeutic markets globally.<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding preclinical development plans and platform expectations for ISM0900. Actual results may differ due to risks including preclinical and clinical outcomes, regulatory pathways, and competitive dynamics.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Insilico Medicine (HKG: 3696) announced the nomination of ISM0900 \u2014 a potent, highly selective, oral&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,11,6],"tags":[69,4514,164],"class_list":["post-72366","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","category-rd","tag-cvd","tag-hkg-3696","tag-insilico-medicine"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v28.2) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Insilico Medicine Nominates ISM0900, AI\u2011Designed Oral Lp(a) Inhibitor, as 9th Preclinical Candidate of 2026 - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Insilico Medicine (HKG: 3696) announced the nomination of ISM0900 \u2014 a potent, highly selective, oral small\u2011molecule inhibitor powered by AI \u2014 as a Preclinical Candidate (PCC). Targeting lipoprotein(a), or Lp(a), for cardiovascular risk management, ISM0900 marks the 9th PCC nominated by Insilico Medicine since the start of 2026.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=72366\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Insilico Medicine Nominates ISM0900, AI\u2011Designed Oral Lp(a) Inhibitor, as 9th Preclinical Candidate of 2026\" \/>\n<meta property=\"og:description\" content=\"Insilico Medicine (HKG: 3696) announced the nomination of ISM0900 \u2014 a potent, highly selective, oral small\u2011molecule inhibitor powered by AI \u2014 as a Preclinical Candidate (PCC). Targeting lipoprotein(a), or Lp(a), for cardiovascular risk management, ISM0900 marks the 9th PCC nominated by Insilico Medicine since the start of 2026.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=72366\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-08-12T04:23:59+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-08-12T04:24:00+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=72366#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=72366\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Insilico Medicine Nominates ISM0900, AI\u2011Designed Oral Lp(a) Inhibitor, as 9th Preclinical Candidate of 2026\",\"datePublished\":\"2026-08-12T04:23:59+00:00\",\"dateModified\":\"2026-08-12T04:24:00+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=72366\"},\"wordCount\":381,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"CVD\",\"HKG: 3696\",\"Insilico Medicine\"],\"articleSection\":[\"Company\",\"Drug\",\"R&amp;D\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=72366#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=72366\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=72366\",\"name\":\"Insilico Medicine Nominates ISM0900, AI\u2011Designed Oral Lp(a) Inhibitor, as 9th Preclinical Candidate of 2026 - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-08-12T04:23:59+00:00\",\"dateModified\":\"2026-08-12T04:24:00+00:00\",\"description\":\"Insilico Medicine (HKG: 3696) announced the nomination of ISM0900 \u2014 a potent, highly selective, oral small\u2011molecule inhibitor powered by AI \u2014 as a Preclinical Candidate (PCC). Targeting lipoprotein(a), or Lp(a), for cardiovascular risk management, ISM0900 marks the 9th PCC nominated by Insilico Medicine since the start of 2026.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=72366#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=72366\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=72366#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Insilico Medicine Nominates ISM0900, AI\u2011Designed Oral Lp(a) Inhibitor, as 9th Preclinical Candidate of 2026\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Insilico Medicine Nominates ISM0900, AI\u2011Designed Oral Lp(a) Inhibitor, as 9th Preclinical Candidate of 2026 - Insight, China&#039;s Pharmaceutical Industry","description":"Insilico Medicine (HKG: 3696) announced the nomination of ISM0900 \u2014 a potent, highly selective, oral small\u2011molecule inhibitor powered by AI \u2014 as a Preclinical Candidate (PCC). Targeting lipoprotein(a), or Lp(a), for cardiovascular risk management, ISM0900 marks the 9th PCC nominated by Insilico Medicine since the start of 2026.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=72366","og_locale":"en_US","og_type":"article","og_title":"Insilico Medicine Nominates ISM0900, AI\u2011Designed Oral Lp(a) Inhibitor, as 9th Preclinical Candidate of 2026","og_description":"Insilico Medicine (HKG: 3696) announced the nomination of ISM0900 \u2014 a potent, highly selective, oral small\u2011molecule inhibitor powered by AI \u2014 as a Preclinical Candidate (PCC). Targeting lipoprotein(a), or Lp(a), for cardiovascular risk management, ISM0900 marks the 9th PCC nominated by Insilico Medicine since the start of 2026.","og_url":"https:\/\/flcube.com\/?p=72366","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-08-12T04:23:59+00:00","article_modified_time":"2026-08-12T04:24:00+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=72366#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=72366"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Insilico Medicine Nominates ISM0900, AI\u2011Designed Oral Lp(a) Inhibitor, as 9th Preclinical Candidate of 2026","datePublished":"2026-08-12T04:23:59+00:00","dateModified":"2026-08-12T04:24:00+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=72366"},"wordCount":381,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["CVD","HKG: 3696","Insilico Medicine"],"articleSection":["Company","Drug","R&amp;D"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=72366#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=72366","url":"https:\/\/flcube.com\/?p=72366","name":"Insilico Medicine Nominates ISM0900, AI\u2011Designed Oral Lp(a) Inhibitor, as 9th Preclinical Candidate of 2026 - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-08-12T04:23:59+00:00","dateModified":"2026-08-12T04:24:00+00:00","description":"Insilico Medicine (HKG: 3696) announced the nomination of ISM0900 \u2014 a potent, highly selective, oral small\u2011molecule inhibitor powered by AI \u2014 as a Preclinical Candidate (PCC). Targeting lipoprotein(a), or Lp(a), for cardiovascular risk management, ISM0900 marks the 9th PCC nominated by Insilico Medicine since the start of 2026.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=72366#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=72366"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=72366#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Insilico Medicine Nominates ISM0900, AI\u2011Designed Oral Lp(a) Inhibitor, as 9th Preclinical Candidate of 2026"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"","_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/72366","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=72366"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/72366\/revisions"}],"predecessor-version":[{"id":72368,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/72366\/revisions\/72368"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=72366"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=72366"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=72366"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}